Global Vocal Biomarkers Market, By Therapeutic
Applications, End User, and Geography - Trends, Analysis
and Forecast till 2028
Sound vibrations are used as part of therapeutic healing for various mental health conditions
such as depression and anxiety. Recent research studies, however, have greatly broadened its
application into diagnosis of diseases. Biomarkers in the voice of a person have been linked to
disorders such as depression, coronary artery disease, and anxiety. On successful completion of
clinical trials, HIPAA compliant vocal biomarker system would serve as much more effective
alternative to current diagnostic techniques such as MRI, X-Ray, and CT scan. Research is also
underway for identifying vocal biomarkers in diagnosis of Parkinson’s disease, traumatic brain
injury, cognitive impairment, and respiratory disorders, which would open up a highly lucrative
avenue for growth for players in this industry. Companies dealing with voice technology are
sampling data to provide accurate results. For instance, Beyond Verbal, Inc. has been
researching on vocal biomarkers since 1996, and has collected over 2.5 million voice samples in
over 40 different languages.
Request Sample Copy of Research Report @
https://www.coherentmarketinsights.com/insight/request-sample/101
While currently in its very nascent stage with an estimated value of US$ 6.4 million in 2017,
the global vocal biomarkers market is expected to expand at a CAGR of 65.7% during the
forecast period (2017 – 2028).
Growing Psychological and Cardiovascular Disease Prevalence: A Highly Conducive Growth
Environment
Around 350 million people across the globe suffered from depression (WHO, 2016) and
approximately 10 million people suffered from Parkinson’s disease globally (Parkinson’s disease
Foundation, 2016). Over 235 million people suffered from asthma globally (2016), according to
the European Respiratory Society. Diagnosis of these diseases is expensive and thus, is out of
reach for most people in emerging economies. This results in high mortality rates in these
regions. Vocal biomarker technology systems would act as an ideal cost-effective primary
diagnostic tool that could help discern if the patient needs to further opt for expensive